Baseline Parameter | Items | Total; n = 121 | Metformin n = 42 | Pioglitazone n = 40 | MET + PIO n = 39 |
---|---|---|---|---|---|
Sex | Male (%) | 74 (61.2) | 23 (54.8) | 25 (62.5) | 26 (66.7) |
Female (%) | 47 (38.8) | 19 (45.2) | 15 (37.5) | 13 (33.3) | |
Age [years] | Mean (SD) | 63.0 (7.5) | 64.2 (7.3) | 61.5 (7.1) | 63.3 (7.9) |
Weight [kg] | Mean (SD) | 92.5 (17.3) | 89.4 (13.8) | 91.9 (16.2) | 96.6 (20.9) |
BMI [kg/m2] | Mean (SD) | 32.2 (5.3) | 31.8 (5.0) | 31.7 (4.3) | 33.1 (6.4) |
Duration of Diabetes Type 2 in [years] | Mean (SD) | 11.1 (6.2) | 12.3 (6.8) | 9.8 (5.8) | 11.0 (5.7) |
Median | 10.0 | 11.0 | 8.0 | 10.0 | |
Range | 1.0 - 31.5 | 3.0 - 31.5 | 1.0 - 28.0 | 1.3 - 29.0 | |
SBP [mmHg] | Mean (SD) | 137.5 (14.0) | 138.8 (16.1) | 137.0 (10.7) | 136.5 (14.9) |
DBP [mmHg] | Mean (SD) | 78.1 (8.4) | 78.5 (10.1) | 77.5 (7.5) | 78.2 (7.2) |
FBG [mmol/L] | Mean (SD) | 8.35 (2.17) | 8.01 (1.96) | 8.83 (2.52) | 8.22 (1.95) |
Insulin units | Mean (SD) | 36.3 (20.9) | 36.3 (20.1) | 37.7 (22.9) | 34.9 (19.9) |
HbA1C [%] | Mean (SD) | 7.34 (0.53) | 7.35 (0.53) | 7.33 (0.53) | 7.34 (0.54) |
MMP-9 [ng/mL] | Mean (SD) | 566.0 (266.2) | 589.7 (309.1) | 530.9 (226.4) | 576.5 (257.1) |
hs-CRP [mg/L] | Mean (SD) | 4.19 (4.14) | 4.77 (4.91) | 3.98 (3.43) | 3.76 (3.93) |
hs-CRP ≤ 10 [mg/L]; | Mean (SD) | 3.21 (2.54) | 3.17 (2.37) | 3.41 (2.87) | 3.05 (2.39) |
Creatinine [mg/dL] | Mean (SD) | 0.84 (0.19) | 0.81 (0.19) | 0.86 (0.17) | 0.86 (0.22) |
Conc. BP-lower. ther. | n (%) | 106 (87.6) | 39 (92.9) | 37 (92.5) | 30 (76.9) |
Conc. lipid-lower. ther. | n (%) | 59 (48.8) | 22 (52.4) | 19 (47.5) | 18 (46.2) |
Conc. hypertension | n (%) | 104 (86.0) | 37 (88.1) | 36 (90.0) | 31 (79.5) |
Conc. CHD | n (%) | 23 (19.0) | 13 (31.0) | 7 (17.5) | 3 (7.7) |